Strategies in the management of alemtuzumab-related side effects

• Published in: Seminars in oncology Vol. 33; no. 2 Suppl 5; p. S29
• Main Authors: Osterborg, Anders, Karlsson, Claes, Lundin, Jeanette, Kimby, Eva, Mellstedt, Håkan
• Format: Journal Article
• Language: English
• Published: United States 01.04.2006
• Subjects: Alemtuzumab; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm - adverse effects; Antineoplastic Agents - adverse effects; Bacterial Infections - prevention & control; Drug Eruptions - prevention & control; Humans; Immunosuppression - adverse effects; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Neutropenia - prevention & control; T-Lymphocytes - drug effects; Virus Diseases - prevention & control

B-cell chronic lymphocytic leukemia has traditionally been treated with alkylating agents and purine analogues. The introduction of alemtuzumab, a CD52 monoclonal antibody with significant clinical activity in chemotherapy refractory B-cell chronic lymphocytic leukemia, is accompanied by a side effe...